#ChugaiPharmaceutical

F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.

For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.

The fiscal year-end dividend for the term ending December 2025 is 147 yen per share (ordinary dividend 72 yen, 100th anniversary commemorative dividend 75 yen), raising the annual dividend to 272 yen. The total dividend amount is 241.92 billion yen, with an effective date of March 27, 2026.

Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.

Chugai Pharmaceutical Co., Ltd. completed the full acquisition of Renalis Pharma Co., Ltd. on November 27, 2025, and finalized the absorption-type merger with Chugai Pharmaceutical Co., Ltd. as the surviving company and Renalis Pharma Co., Ltd. as the absorbed company on December 30, 2025.